SIRPant Immunotherapeutics Overview

  • Founded
  • 2020
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $1.5M
Latest Deal Amount
  • Investors
  • 1

SIRPant Immunotherapeutics General Information

Description

Developer of cancer-specific immunotherapy intended to focus on the development of novel autologous cell therapy for solid tumors. The company's technology employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells resulting in a polyclonal immune response against multiple tumor antigens, helping doctors to treat solid tumors efficiently.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1590 Bunker Court
  • Chambersburg, PA 17202-8040
  • United States
+1 (610) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SIRPant Immunotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 30-Nov-2020 $1.5M 00.00 Completed Startup
To view SIRPant Immunotherapeutics’s complete valuation and funding history, request access »

SIRPant Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer-specific immunotherapy intended to focus on the development of novel autologous cell therapy for sol
Biotechnology
Chambersburg, PA
4 As of 2021
00.00
0000000000 0 00.00

0000000

bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Philadelphia, PA
00 As of 0000
00000
00000000000 00000

00000000

cing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
0000000000000
Windsor, United Kingdom
0000
00.00 0000-00-00
0000000000 0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SIRPant Immunotherapeutics Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
0000000000 000000 Venture Capital-Backed Windsor, United Kingdom 0000 0000000000 0 0000
000 00000000 Formerly VC-backed Burlingame, CA 00 00000 00000000 00000
0000 00000000 Venture Capital-Backed Brisbane, CA 00 000.00 000000000 - 000.00
0000000 0000000000 Venture Capital-Backed Bedford, MA 000.00 0000000000 0 000.00
You’re viewing 5 of 10 competitors. Get the full list »

SIRPant Immunotherapeutics Executive Team (3)

Name Title Board Seat Contact Info
Robert Towarnicki Founder, President, Chairman & Chief Executive Officer
Richard Fitzgerald Chief Financial Officer
Dennis Kim MD Senior Vice President & Chief Medical Officer
To view SIRPant Immunotherapeutics’s complete executive team members history, request access »

SIRPant Immunotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SIRPant Immunotherapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioAdvance Venture Capital Minority 000 0000 000000 0
To view SIRPant Immunotherapeutics’s complete investors history, request access »